Zealand Pharma A/S (0NZU.L)
| Previous close | 118.72 |
| Open | 123.20 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 123.20 - 124.50 |
| 52-week range | 123.20 - 124.50 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 15 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireZealand Pharma Announces Financial Results for the First Quarter of 2024
Company announcement - No. 26 / 2024 Zealand Pharma Announces Financial Results for the First Quarter of 2024 Strong performance in the first quarter of 2024 paving the way for important data read-outs across differentiated obesity assets in the second quarter. Strong topline results announced in Boehringer Ingelheim Phase 2 clinical trial for survodutide in MASHPDUFA date for glepaglutide in SBS set by US FDA for December 22, 2024 PDUFA date for dasiglucagon in CHI for up to three weeks of dosi
- Globe Newswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 25 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May 12, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by per
- Globe Newswire
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results
Press Release – No. 4 / 2024 Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results Copenhagen, Denmark, May 9, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 16, 2024, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter of 2024. Presenting dur
